PetVivo Holdings, Inc. (PETV) stock
Close on Oct 19, 2026Market cap $27.79MP/E –Yield –
PetVivo Holdings, Inc. saw revenue fall 9.5% to $1.18M over the twelve months to Jun 30, 2026. Free cash flow was -$6.12M. At the latest close the market valued the company at $27.79M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $27.79M
- P/E ratio
- –
- Price to sales
- 23.52
- Price to book
- 20.49
- Dividend yield
- –
- Free cash flow yield
- -22.00%
Fundamentals
- Revenue
- $1.18M
- Net income
- -$9.78M
- EPS, diluted
- -$0.31
- Free cash flow
- -$6.12M
- Book value per share
- $0.04
- Diluted shares
- 37M
Trading
- Previous close
- $0.75
- Open
- $0.75
- Day's range
- $0.75 – $0.75
- Volume
- 0
- Average volume (20 days)
- 18,781
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | PETV | S&P 500 | Difference | PETV per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | 0.0% | +0.6% | −0.6 pts | ||
| 3 months | -2.4% | +3.4% | −5.8 pts | ||
| Year to date | -34.2% | +13.3% | −47.5 pts | ||
| 1 year | -44.4% | +16.6% | −61.1 pts | ||
| 3 years | -59.2% | +86.4% | −145.6 pts | -25.9% | +23.1% |
| 5 years | -73.7% | +81.9% | −155.5 pts | -23.4% | +12.7% |
| 10 years | -79.7% | +318.9% | −398.5 pts | -14.7% | +15.4% |
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases PetVivo filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About PetVivo
Surgical & Medical Instruments & Apparatus
PetVivo Holdings, Inc. is an emerging biomedical device company that manufactures, commercializes, and licenses medical devices and therapeutics for animals. Its lead commercial product is Spryng with OsteoCushion Technology, an intra-articular injectable device composed of biocompatible, naturally derived collagen, elastin, and heparin particles designed to manage lameness and joint afflictions such as osteoarthritis in dogs and horses. The company also maintains a development pipeline of seventeen therapeutic devices targeted for veterinary and human applications. Customers consist of licensed veterinary practices, reached through wholesale distribution partners such as Vedco and Clipper, as well as direct-to-clinic and governmental accounts.
Company profile, executives and historyPetVivo stock: common questions
What is PetVivo's stock price?
PETV closed at $0.75 on Oct 19, 2026, up 0.00% on the day.
What is PetVivo's market cap?
PetVivo was worth $27.79M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is PETV's P/E ratio?
PetVivo lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.31), so it has no meaningful P/E ratio.
How much revenue does PetVivo make?
PetVivo reported revenue of $1.18M for the twelve months to Jun 30, 2026, down 9.5% from a year earlier.
Does PetVivo pay a dividend?
No. PetVivo has not paid a cash dividend over the last twelve months.
How has PETV stock performed over the past year?
Including dividends, PETV returned -44.4% over the past year, against +16.6% for the S&P 500.
Who are PetVivo's competitors?
Companies most similar to PetVivo by business, industry and size include HRGN, VJET, PLSE, VYCO, OSRH.
See a number that looks wrong?